"Pharmaceutical Speed Reading Society" Heng Rui senior executives resigned a number of drugs will soon be approved in China.

July 27, 2020 / Medical Information List: The Drug Administration releases the results of medical device supervision and sampling; several drugs are about to be approved in China; fda-licensed the first COVID-19 test for screening asymptomatic population; start-up Tubulis A round financing 10.7 million euros; anti-AIDS class 1 new drug Eddie Pharmaceuticals submitted the first NDA ... Daily fresh medicine to hear medical news, fast-reading society with you to pay attention! Part 1 Policy Brief July 26 The country added 57 confirmed local cases July 26 0-24, 31 provinces (autonomous regions, municipalities directly under the Central Government) and Xinjiang Production and Construction Corps reported 61 new confirmed cases, of which 4 cases were imported from abroad (2 cases in Inner Mongolia, 1 case in Fujian, 1 case in Sichuan), 57 cases in the mainland (41 cases in Xinjiang, 14 cases in Liaoning, 2 cases in Jilin);
(National Health and Welfare Commission) Drug Administration today released the results of the National Medical Device Supervision and Inspection of the State Drug Administration issued a notice, the content scored: in order to strengthen the quality supervision and management of medical devices, to ensure the safe and effective use of medical device products, the State Drug Administration organization of ultrasound Doppler fetal monitoring instrument, high-frequency surgical equipment, respiratory attraction ducts (suction tube) and other 10 varieties of products carried out quality supervision and sampling, a total of 34 batches of products do not meet the standards.
(State Drug Administration) Part 2 production and observation Hengrui several senior executives resigned recently, Jiangsu Hengrui Pharmaceuticals issued a notice that the company's board of directors recently received the company's deputy general manager Jiang Xinhua, Sun Hui, Liu Ji, Mr. Li Kejian's resignation report.
Mr. Jiang Xinhua, Sun Hui, Liu Ji and Mr. Li Kejian applied to resign as Deputy General Manager of the Company because of their age, and the resignation report shall take effect from the date of service to the Board of Directors of the Company.
Tubulis announced the completion of a 10.7 million euro round of a 10.7 million euro funding by BioMed Partners and High-Tech Gr?nderfonds, with institutions such as Venture Partners, Coparion, Bayern Kapital and OCCIDENT, the start-up Of touts.
funds will be used to accelerate the development of new high-stability and highly effective antibody conjugate drugs.
(PharmaRubik Cube) AstraZeneca and I3 jointly developed the antibody conjugate drug AstraZeneca and Sansan Co., Ltd. reached a new global development and commercialization agreement with First SanCo.
DS-1062 is a potentially heavy-impact new drug that promises to redefine the standard of treatment for lung, breast cancer and many other cancers.
(instant medicine) The FDA has urgently authorized the first COVID-19 diagnostic test for extensive screening, including testing for people who have shown no symptoms and have not been exposed to confirmed cases, and allowed combined sample tests to be used to screen asymptomatic populations.
authorized for this emergency use is the LabCorp COVID-19 RT-PCR test.
(Sina Pharmaceutical News) FDA awarded Sarepta/Roche SRP-900 treatment DMD fast-track eligibility Sarepta recently announced that the U.S. FDA has awarded SRP-9001 treatment of Du's muscular dystrophy (DMD) fast-track eligibility.
SRP-9001 is a gene transfer therapy in which genes encoding micro-malnourished proteins are transmitted to muscle tissue to produce the target protein, the micromaltrophic protein.
Roche has signed a $2.85 billion license agreement with Sarepta, acquiring exclusive rights to SRP-9001 outside the United States.
(Bio Valley) Johnson and Johnson Imbruvica Joint Lytox IDR1 treatment CLL approved by the European Union CHMP Johnson's Janssen Pharmaceuticals has announced that the European Medicines Agency (EMA) Human Pharmaceutical Products Committee (CHMP) has issued a positive review, recommending the approval of Imbruvica, united lysaxatomatoma first-line treatment of chronic lymphocytic leukemia (C) adult patients.
now, CHMP's positive comments will now be reviewed by the European Commission, which usually makes a final review decision within two months.
(BioValley) GlaxoSmithKline Blenrep in the U.S. and Europe is about to be approved for listing, GlaxoSmithKline announced that the European Medicines Agency (EMA) Human Pharmaceutical Products Committee (CHMP) has issued a positive review, recommending approval of Blenrep, a target B-cell mature antigen antibody antibody antibody drug Co-ops for: as a monodrug therapy for the treatment of adult patients with multiple myeloma who have previously received at least 4 therapies and whose disease is resistant to at least one protease inhibitor, an immunomodulator, an anti-CD38 antibody, and which has been confirmed to be progressing during the last treatment.
now, CHMP's positive comments will now be reviewed by the European Commission, which usually makes a final review decision within two months.
(Biovalley) treatment of gastrointestinal interstitonoma avapritinib will be approved by the European Union in September, Blueprint announced that the European Medicines Agency (EMA) Human Pharmaceutical Products Committee (CHMP) has issued an active review of the recommendation to conditionally approve the targeting of the anti-cancer drug avapritinib, as a monotherapy for the treatment of patients carrying platelet-derived growth factor receptor alpha dats dilated or adult transnomutification.
now, CHMP's positive comments will now be reviewed by the European Commission, which is expected to make a final review decision by the end of September.
(BioValley) Mersadong SGLT-2 inhibitor "Atogre Net" is about to be approved in China Mersadong recently submitted in China Atogli net tablet listing application into the "in approval" stage, is expected to be approved in the near future, China's 4th approved listing of sodium-glucose co-transport protein 2 (SGLT-2) inhibitor.
Etogre Net is the FDA's 4th SGLT2 inhibitor approved by the FDA following The Caglenet (Johnson and Johnson), Dagre Net (AstraZeneca), and Ngrenet (Bollinger Ingerheim/Lilly).
(Pharma Cube) AstraZeneca/Pfizer "cephalosporine" is about to be approved in China before AstraZeneca/Pfizer's application for a listing in China for injection cephalosporine is in the administrative approval stage and is expected to be approved for listing in China in the near future.
cephalosporine is a fifth-generation antibiotic that is clinically used to treat acute bacterial skin/skin structural infections and community acquired bacterial pneumonia.
(Pharmaceutical Rubik's Cube) Howson Pharmaceuticals "Engler Net" first imitation is about to be approved recently, Howson Pharmaceuticals submitted four types of generic Engel net tablet listing application into the "in the approval" stage, is expected to be approved in the near future to become the first imitation in China.
Ngrenet is a sodium-glucose co-transporter 2 inhibitor developed by Bolinger Ingham for type 2 diabetes and the first sugar-reducing drug to be shown to have cardiovascular benefits.
(Pharmaceutical Rubik's Cube) First Sound Pharmaceuticals Class 1 new drug "Idala feng right-handedalcohol injection" is about to be approved before the date, first sound Dongyuan Pharmaceuticals submitted a class 1 new drug Idala feng right- alcohol injection listing application into the "in approval" stage, is expected to be approved in the near future, for the treatment of ischemic stroke.
Idalafon rightalcohol injection is an innovative neuroprotective agent, with a 4:1 ratio combination of two active ingredients Idarafon and right- alcohol, the use of two ingredients to remove free radicals, anti-inflammatory and improve the hemoglobin barrier and other multiple mechanisms, can significantly reduce and improve acute ischemic encephalopathy caused by nerve damage.
(Pharma Rubik's Cube) Anti-AIDS Class 1 new drug Eddie Pharmaceuticals submitted the first NDA 25, Eddy Pharmaceuticals in CDE submitted a class 1 new drug ACC007 tablets on the market application, and received acceptance.
this is an anti-AIDS candidate and the first new drug application (NDA) submitted by Eddy Pharmaceuticals.
ACC007 is a new generation of non-nucleoside reverse transcriptase inhibitors that block viral transcription and replication by binding and inhibiting HIV reverse transcriptase activity.
(Pharmaceutical Mission)